Considering the close correlation between the frequency of PD-1+ macrophages and prognosis of GC patients, a therapeutic strategy targeting the phagocytotic activity of macrophages might be effective for the treatment of GC patients. The gene discussed is PDCD1; the disease is gastric cancer.